Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Optimising the management of childhood acute diarrhoeal disease using a rapid test-and- treat strategy and/or Lactobacillus reuteri DSM 17938: a multicentre, randomised, controlled, factorial trial in Botswana

  • 2022-04
  • BMJ Global Health 7(4)
    • J. Pernica
    • T. Arscott-Mills
    • A. Steenhoff
    • M. Mokomane
    • Banno Moorad
    • Mbabi Bapabi
    • K. Lechiile
    • Oarabile Mangwegape
    • Boswa Batisani
    • Norah Mawoko
    • Charles Muthoga
    • T. Vanniyasingam
    • Joycelyne E Ewusie
    • Amy Lowe
    • Janice M Bonsu
    • Alemayehu Mekonnen Gezmu
    • M. Smieja
    • L. Mazhani
    • K. Størdal
    • L. Thabane
    • M. Kelly
    • D. Goldfarb

Abstract

Introduction: The study aim was to determine if rapid enteric diagnostics followed by the provision of targeted antibiotic therapy ('test-and-treat') and/or Lactobacillus reuteri DSM 17938 would improve outcomes in children hospitalised in Botswana with acute gastroenteritis.

Methods: This was a multicentre, randomised, factorial, controlled, trial. Children aged 2-60 months admitted for acute non-bloody diarrhoea to four hospitals in southern Botswana were eligible. Participants were assigned to treatment groups by web-based block randomisation. Test-and-treat results were not blinded, but participants and research staff were blinded to L. reuteri/placebo assignment; this was dosed as 1×108 cfu/mL by mouth daily and continued for 60 days. The primary outcome was 60-day age-standardised height (HAZ) adjusted for baseline HAZ. All analyses were by intention to treat. The trial was registered at Clinicaltrials.gov.

Results: Recruitment began on 12 June 2016 and continued until 24 October 2018. There were 66 participants randomised to the test-and-treat plus L. reuteri group, 68 randomised to the test-and-treat plus placebo group, 69 to the standard care plus L. reuteri group and 69 to the standard care plus placebo group. There was no demonstrable impact of the test-and-treat intervention (mean increase of 0.01 SD, 95% CI -0.14 to 0.16 SD) or the L. reuteri intervention (mean decrease of 0.07 SD, 95% CI -0.22 to 0.08 SD) on adjusted HAZ at 60 days.

Conclusions: In children hospitalised for acute gastroenteritis in Botswana, neither a test-and-treat algorithm targeting enteropathogens, nor a 60-day course of L. reuteri DSM 17938, were found to markedly impact linear growth or other important outcomes. We cannot exclude the possibility that test-and-treat will improve the care of children with significant enteropathogens (such as Shigella) in their stool.

Trial registration number: NCT02803827.

Keywords: Child health; Individual randomized trial; Medical microbiology.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus reuteriAdjusted Height-for-Age Z ScoreNeutral
Small
Lactobacillus reuteri DSM 17938Improved Age-Standardized HeightNeutral
Small
Lactobacillus reuteri HA-188Improved GrowthNeutral
Small
Back to top